Genmab A/S: Genmab Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting

Epcoritamab featured in multiple data disclosures, including four oral presentations Results presented from the phase 1b/2 EPCORE NHL-2 trial of epcoritamab combined with standard salvage

Related Keywords

Japan ,Louisiana ,United States ,New Orleans ,Tokyo ,Denmark ,Copenhagen ,Køavn ,New Jersey ,Netherlands ,American ,David Freundel ,Judith Klimovsky ,Andrew Carlsen ,Exposition Of The American Society Hematology ,Product Communications ,Macrophage Propertiesj Immunol ,Data From The Observational National Lymphocare Study ,Twitter ,National Institutes Of Health ,Drug Administration ,Exchange Commission ,Leukaemia Foundation ,Development Of Novel Anti ,European Medicines Agency ,Lymphoma Research Foundation ,Annual Meeting ,American Society ,Executive Vice President ,Chief Development Officer ,Diffuse Largeb Cell Lymphoma ,Follicular Lymphoma ,Biologics License Application ,Priority Review ,Marketing Authorization Application ,Forward Looking Statements ,Media Release ,Annual Report ,Y Shaped Genmab ,Diffuse Largeb Cell ,Stat Facts ,Accessed November ,Research Foundation ,Subsequent Therapy ,Data From ,Observational National Lymphocare ,Treatment Patterns ,Patients With Diffuse Largeb Cell Lymphoma ,Clinically Utilized ,Directed Antibodies ,Macrophage Properties ,Novel Anti Cd ,Cell Surface ,Cancer Sci ,Investor Relations ,Vice President ,Genmab ,Howcases ,Data ,Rom ,Obust ,Development ,Program ,Valuating ,Epcoritamab ,Uobody ,D3xcd20 ,Patients ,Cross ,Road ,Orange ,Fell ,Lymphomas ,4th ,Nnual ,Meeting ,